Association between adjunctive rifampin and gentamicin use and outcomes for patients with staphylococcal prosthetic valve endocarditis: a propensity-score adjusted retrospective cohort study
- PMID: 39441462
- DOI: 10.1007/s15010-024-02421-8
Association between adjunctive rifampin and gentamicin use and outcomes for patients with staphylococcal prosthetic valve endocarditis: a propensity-score adjusted retrospective cohort study
Abstract
Purpose: Although guidelines recommend adjunctive rifampin and gentamicin use for patients with staphylococcal prosthetic valve endocarditis (PVE), evidence behind the recommendation is limited and conflicting.
Methods: We performed a retrospective cohort study of all patients with staphylococcal PVE within the Veterans Health Administration during 2003-2021. Patients were identified with diagnostic codes for prosthetic valves and positive blood cultures for Staphylococcus species and confirmed via manual chart reviews. The primary outcome was the composite of all-cause mortality or recurrence of staphylococcal PVE within one year from diagnosis. Inverse probability of treatment weighting (IPTW) was used to estimate the probability of individuals receiving rifampin using propensity scores. IPTW-adjusted multivariable Cox regression analysis was used to compare outcomes between patients who received rifampin and gentamicin, and those did not.
Results: Among 373 patients with staphylococcal PVE, 275 (73.7%) and 225 (60.3%) received at least one dose of rifampin and gentamicin, respectively. The incidence of staphylococcal PVE increased from 0.47 (2003-11) to 0.77 (2012-21) per 10,000 hospitalizations. Gentamicin use declined over time (70.1% in 2003-2011 to 54.8% in 2012-2021, p = 0.04) while rifampin use did not change significantly (76.1% in 2003-2011 to 72.4% in 2012-2021, p = 0.43). The composite outcome was observed in 209 (56.0%). Neither rifampin use (adjusted hazard ratio [HR] 0.77, 95% CI 0.48-1.24) and gentamicin use (adjusted HR 1.11, 95% CI 0.71-1.74) was associated with the composite outcome.
Conclusion: No significant association was observed between adjunctive rifampin or gentamicin use and improved outcomes.
Keywords: Staphylococcal species; Epidemiology; Gentamicin; Prosthetic valve endocarditis; Rifampin.
© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Similar articles
-
Gentamicin may have no effect on mortality of staphylococcal prosthetic valve endocarditis.J Infect Chemother. 2018 Jul;24(7):555-562. doi: 10.1016/j.jiac.2018.03.003. Epub 2018 Apr 6. J Infect Chemother. 2018. PMID: 29628387
-
Rifampin for Surgically Treated Staphylococcal Infective Endocarditis: A Propensity Score-Adjusted Cohort Study.Ann Thorac Surg. 2016 Jun;101(6):2243-50. doi: 10.1016/j.athoracsur.2015.11.015. Epub 2016 Feb 10. Ann Thorac Surg. 2016. PMID: 26872729
-
Is Rifampin Use Associated With Better Outcome in Staphylococcal Prosthetic Valve Endocarditis? A Multicenter Retrospective Study.Clin Infect Dis. 2021 May 4;72(9):e249-e255. doi: 10.1093/cid/ciaa1040. Clin Infect Dis. 2021. PMID: 32706879
-
Advancements and Challenges in the Management of Prosthetic Valve Endocarditis: A Review.Pathogens. 2024 Nov 26;13(12):1039. doi: 10.3390/pathogens13121039. Pathogens. 2024. PMID: 39770299 Free PMC article. Review.
-
Valvular Heart Disease in Adults: Infective Endocarditis.FP Essent. 2017 Jun;457:30-38. FP Essent. 2017. PMID: 28671807 Review.
References
-
- Glaser N, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. Prosthetic valve endocarditis after surgical aortic valve replacement. Circulation. 2017;136(3):329–31. https://doi.org/10.1161/circulationaha.117.028783 . - DOI - PubMed
-
- Muñoz P, Kestler M, De Alarcon A, Miro JM, Bermejo J, Rodríguez-Abella H, et al. Current epidemiology and outcome of infective endocarditis: a multicenter, prospective, cohort study. Med (Baltim). 2015;94(43):e1816. https://doi.org/10.1097/md.0000000000001816 . - DOI
-
- Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr., Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of vomplications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435–86. https://doi.org/10.1161/cir.0000000000000296 . - DOI - PubMed
-
- Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023 ESC guidelines for the management of endocarditis. Eur Heart J. 2023;44(39):3948–4042. https://doi.org/10.1093/eurheartj/ehad193 . - DOI - PubMed
-
- Chuard C, Herrmann M, Vaudaux P, Waldvogel FA, Lew DP. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother. 1991;35(12):2611–6. https://doi.org/10.1128/aac.35.12.2611 . - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical